Moat Ross bought KNSA
January 15, 2026 · Form 4 insider transaction
Moat Ross bought 879 shares of Kiniksa Pharmaceuticals International, plc at $24.16 per share, a transaction worth $21.2K. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 78 days after the transaction.
Direction
Acquired (buy-side)
Shares
879
Price
$24.16
Total value
$21.2K
InsiderMoat Ross
RoleOfficer
SecurityClass A Ordinary Share
Transaction codeA: Grant or award
Transaction dateJanuary 15, 2026
Filing dateApril 3, 2026
Shares owned after10,294
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2025 to January 15, 2026. The acquisition of these shares was exempt pursuant to Rule 16b-3(e).